Advertisement

Lipidsenkende Mittel

  • Gerald Klose
  • Ulrich Schwabe

Zusammenfassung

Die Verordnungen der Statine haben auch 2013 weiter zugenommen. Dominierendes Präparat ist weiterhin Simvastatin. Den stärksten Zuwachs erzielte allerdings Atorvastatin durch seine besonders preisgünstigen Generika. Andere Statine, Ezetimibpräparate und Fibrate waren dagegen rückläufig. Nicotinsäurepräparate sind nicht mehr unter den meistverordneten Arzneimitteln vertreten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; on behalf of the SHARP Investigators (2011): The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 181–2192Google Scholar
  2. Cholesterol Treatment Trialists' (CTT) Collaborators (2005): Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278Google Scholar
  3. Cholesterol Treatment Trialists‘ (CTT) Collaborators (2008): Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117–125Google Scholar
  4. Cholesterol Treatment Trialists' (CTT) Collaboration (2010): Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681Google Scholar
  5. Coronary Drug Project (1975): Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381Google Scholar
  6. De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N (1999): Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 99: 779–785PubMedCrossRefGoogle Scholar
  7. Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (2011): ESC/EAS/DGK Pocket-Leitlinien: Diagnostik und Therapie der Dyslipidämien. Internet: http://leitlinien.dgk.org/images/pdf/leitlinien_pocket/2012_pll_25_dys.pdf
  8. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators (2013): Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368: 1279–1290PubMedCrossRefGoogle Scholar
  9. European Medicines Agency (2013): European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn. Internet: http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2013/01/WC500137453.pdf
  10. Hayward A, Krumholz H, Zulman DM, Timbie JW, Vijan S (2010): Optimizing statin treatment for primary prevention of coronary artery disease. Ann Int Med 152: 69–77PubMedGoogle Scholar
  11. Heart Protection Study Collaborative Group (2011): C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469–476PubMedCentralCrossRefGoogle Scholar
  12. HPS2-THRIVE Collaborative Group (2013): HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34: 1279–1291PubMedCentralCrossRefGoogle Scholar
  13. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011): Ezetimib bei Hypercholesterinämie – Abschlussbericht A10-02. Internet: www.iqwig.de/download/A10-02_Abschlussbericht_Ezetimib_bei_Hypercholesterinaemie.pdf
  14. Jun M, Foote C, Lv L, Neal B, Patel A, Nicholls S, Grobbee DE, Cass A, Chalmers A, Perkovic V (2010): Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875–1884PubMedCrossRefGoogle Scholar
  15. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators (2008): Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431–1443PubMedCrossRefGoogle Scholar
  16. Klose G (2011): Möglichkeiten und Grenzen der modernen Lipidtherapie. Internist 52: 328–335PubMedCrossRefGoogle Scholar
  17. Klose G, Beil FU, Dieplinger H, von Eckardstein A, Föger B, Gouni-Berthold I, Koenig W, Kostner GM, Landmesser U, Laufs U, Leistikow F, März W, Merkel M, Müller-Wieland D, Noll G, Parhofer KG, Paulweber B, Riesen W, Schaefer JR, Steinhagen-Thiessen E, Steinmetz A, Toplak H, Wanner C, Windler E (2014): Neue AHA- und ACC-Leitlinie zur Risikoreduktion von Herz-Kreislauf-Erkrankungen durch Cholesterinsenkung, Stellungnahme der D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e. V., der Österreichischen Atherosklerose Gesellschaft und der Arbeitsgruppe Lipide und Atherosklerose (AGLA) der Schweizer Gesellschaft für Kardiologie. Internist 55: 601–606PubMedGoogle Scholar
  18. Koenig W, Marx N, Thiery J, Klose G (2012): Kommentar zu den neuen Leitlinien (2011) der Europäischen Gesellschaft für Kardiologie zum Management von Dyslipidämien. Kardiologe 6: 210–216CrossRefGoogle Scholar
  19. Krumholz HM, Hayward RA (2010): Shifting views on lipid lowering therapy. BMJ 341: 332–333CrossRefGoogle Scholar
  20. Libby P (2013): Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 368: 2004–2013PubMedCrossRefGoogle Scholar
  21. Lipid Research Clinics Program (1984): Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 351–364, 365–374Google Scholar
  22. Meaney A, Ceballos G, Asbun J, Solache G, Mendoza E, Vela A, Meaney E (2009): The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 49: 838–847PubMedCrossRefGoogle Scholar
  23. Merck (2012): Merck announces HPS2-THRIVE Study of Tredaptive™ (extended-release niacin/ laropiprant) did not achieve primary endpoint. Internet: www.mercknewsroom.com/press-release/prescription-medicine-news/merck-announces-hps2-thrive-study-tredaptive-extended-relea
  24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421. http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm
  25. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013): Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61: 404–410PubMedCrossRefGoogle Scholar
  26. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators (2005): Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29–38Google Scholar
  27. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Inection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators (2005): C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28Google Scholar
  28. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators (2008): N Engl J Med 359: 1343–1356PubMedCrossRefGoogle Scholar
  29. Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389Google Scholar
  30. Schönbeck U, Libby P (2004): Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 (Suppl II): II 18–26CrossRefGoogle Scholar
  31. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators (2012): Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089–2099PubMedCrossRefGoogle Scholar
  32. Shepherd J (2002): Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 359: 2271–2273PubMedGoogle Scholar
  33. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW (2013): 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Nov 12. [Epub ahead of print]Google Scholar
  34. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M (2009): Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361: 2113–2122PubMedCrossRefGoogle Scholar
  35. The ACCORD Study Group (2010): Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574PubMedCentralGoogle Scholar
  36. The AIM-HIGH Investigators (2011): Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255–2267CrossRefGoogle Scholar
  37. The Bezafibrate Infaction prevention (BIP) Study Group (2000): Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infaction Prevention (BIP) study. Circulation 102: 21–27Google Scholar
  38. The FIELD study investigators (2005): Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861Google Scholar
  39. The STABILITY Investigators (2014): Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. N Engl J Med 370: 1702–1711CrossRefGoogle Scholar
  40. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011): ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 32: 1769–818Google Scholar
  41. Willett WC (2012): Dietary fats and coronary heart disease. J Intern Med 272: 13–24PubMedCrossRefGoogle Scholar
  42. Wiesner G, Grimm J, Bittner E (1999): Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61 (Sonderheft 2): S72–S78PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Gerald Klose
    • 1
  • Ulrich Schwabe
    • 2
  1. 1.Pharmakologisches InstitutUniversität HeidelbergHeidelberg
  2. 2.Gemeinschaftspraxis Dres. Thomas Beckenbauer und Stefan MaierhofBremen

Personalised recommendations